| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diet | 33 | 2023 | 205 | 3.410 |
Why?
|
| Diet, Mediterranean | 10 | 2024 | 95 | 2.270 |
Why?
|
| Vitamin E | 19 | 2023 | 41 | 1.700 |
Why?
|
| Cognition Disorders | 15 | 2015 | 970 | 1.360 |
Why?
|
| Cognition | 17 | 2024 | 1276 | 1.300 |
Why?
|
| Feeding Behavior | 13 | 2018 | 90 | 1.280 |
Why?
|
| Cannabis | 2 | 2020 | 9 | 1.270 |
Why?
|
| Humans | 119 | 2024 | 26260 | 1.240 |
Why?
|
| Dementia | 9 | 2023 | 521 | 1.180 |
Why?
|
| Female | 87 | 2024 | 14520 | 1.090 |
Why?
|
| Nutrition Surveys | 6 | 2020 | 20 | 1.030 |
Why?
|
| Cognitive Dysfunction | 9 | 2024 | 989 | 0.970 |
Why?
|
| Dietary Fats | 7 | 2024 | 37 | 0.940 |
Why?
|
| Hypertension | 5 | 2023 | 230 | 0.930 |
Why?
|
| Blood Viscosity | 7 | 2003 | 10 | 0.920 |
Why?
|
| Nutritional Status | 8 | 2022 | 58 | 0.890 |
Why?
|
| Male | 74 | 2024 | 14168 | 0.890 |
Why?
|
| Health Promotion | 4 | 2020 | 154 | 0.880 |
Why?
|
| Folic Acid | 8 | 2012 | 20 | 0.860 |
Why?
|
| Surveys and Questionnaires | 14 | 2019 | 1034 | 0.840 |
Why?
|
| Dietary Supplements | 10 | 2022 | 65 | 0.820 |
Why?
|
| Aging | 9 | 2023 | 1491 | 0.810 |
Why?
|
| Cardiovascular Diseases | 6 | 2022 | 338 | 0.790 |
Why?
|
| Aged | 50 | 2024 | 8595 | 0.770 |
Why?
|
| Food | 5 | 2023 | 33 | 0.770 |
Why?
|
| Nutrition Assessment | 6 | 2019 | 44 | 0.770 |
Why?
|
| Adult | 40 | 2023 | 7516 | 0.740 |
Why?
|
| Diet, Vegetarian | 2 | 2022 | 6 | 0.740 |
Why?
|
| Diet Surveys | 6 | 2017 | 22 | 0.720 |
Why?
|
| Stroke | 2 | 2023 | 255 | 0.700 |
Why?
|
| Life Style | 3 | 2018 | 185 | 0.700 |
Why?
|
| Vitamin B 12 | 5 | 2013 | 12 | 0.700 |
Why?
|
| Middle Aged | 41 | 2020 | 8541 | 0.690 |
Why?
|
| Alzheimer Disease | 13 | 2021 | 2028 | 0.680 |
Why?
|
| Fibrinogen | 8 | 2002 | 23 | 0.650 |
Why?
|
| Polyphenols | 3 | 2020 | 6 | 0.640 |
Why?
|
| Sodium, Dietary | 1 | 2019 | 7 | 0.630 |
Why?
|
| Cross-Sectional Studies | 14 | 2020 | 875 | 0.620 |
Why?
|
| Sodium | 1 | 2019 | 50 | 0.610 |
Why?
|
| Antioxidants | 7 | 2020 | 61 | 0.600 |
Why?
|
| Hypertriglyceridemia | 5 | 2010 | 18 | 0.580 |
Why?
|
| Brain | 7 | 2023 | 1603 | 0.580 |
Why?
|
| Lipoproteins | 3 | 2010 | 9 | 0.580 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 7 | 2005 | 60 | 0.560 |
Why?
|
| Hypolipidemic Agents | 3 | 2010 | 27 | 0.560 |
Why?
|
| Healthy Lifestyle | 1 | 2017 | 37 | 0.550 |
Why?
|
| Trans Fatty Acids | 2 | 2014 | 4 | 0.530 |
Why?
|
| Biomarkers | 7 | 2022 | 556 | 0.530 |
Why?
|
| Social Media | 1 | 2017 | 47 | 0.520 |
Why?
|
| Fatty Acids | 2 | 2014 | 40 | 0.520 |
Why?
|
| Ascorbic Acid | 6 | 2004 | 39 | 0.510 |
Why?
|
| Triglycerides | 8 | 2023 | 56 | 0.510 |
Why?
|
| Chicago | 14 | 2024 | 857 | 0.510 |
Why?
|
| Apolipoprotein E4 | 6 | 2024 | 244 | 0.500 |
Why?
|
| Postprandial Period | 2 | 2010 | 7 | 0.500 |
Why?
|
| Aged, 80 and over | 23 | 2024 | 4594 | 0.490 |
Why?
|
| Carotenoids | 7 | 2021 | 17 | 0.480 |
Why?
|
| Energy Metabolism | 1 | 2015 | 52 | 0.470 |
Why?
|
| Liver Diseases | 1 | 2015 | 33 | 0.470 |
Why?
|
| Obesity | 4 | 2018 | 299 | 0.470 |
Why?
|
| Consumer Behavior | 3 | 2019 | 23 | 0.460 |
Why?
|
| Health Behavior | 5 | 2018 | 160 | 0.460 |
Why?
|
| Liver Transplantation | 1 | 2015 | 80 | 0.450 |
Why?
|
| Young Adult | 10 | 2020 | 1948 | 0.450 |
Why?
|
| Dietary Approaches To Stop Hypertension | 3 | 2024 | 34 | 0.450 |
Why?
|
| Coronary Disease | 6 | 2002 | 64 | 0.440 |
Why?
|
| Hypercholesterolemia | 5 | 2005 | 26 | 0.440 |
Why?
|
| Vitamin B 12 Deficiency | 2 | 2013 | 2 | 0.430 |
Why?
|
| Parkinson Disease | 3 | 2018 | 823 | 0.430 |
Why?
|
| Vitamin B Complex | 3 | 2011 | 5 | 0.430 |
Why?
|
| Vegetables | 6 | 2021 | 24 | 0.390 |
Why?
|
| Reproducibility of Results | 9 | 2023 | 683 | 0.390 |
Why?
|
| Folic Acid Deficiency | 2 | 2009 | 7 | 0.390 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2011 | 303 | 0.390 |
Why?
|
| beta Carotene | 7 | 2004 | 12 | 0.380 |
Why?
|
| Vitamins | 2 | 2011 | 19 | 0.380 |
Why?
|
| Homocysteine | 3 | 2013 | 8 | 0.370 |
Why?
|
| Fenofibrate | 1 | 2010 | 5 | 0.360 |
Why?
|
| Risk Factors | 14 | 2024 | 2221 | 0.350 |
Why?
|
| Neoplasms | 4 | 2020 | 224 | 0.340 |
Why?
|
| Metabolic Syndrome | 1 | 2010 | 60 | 0.340 |
Why?
|
| Survivors | 3 | 2015 | 63 | 0.330 |
Why?
|
| Tea | 2 | 2020 | 6 | 0.330 |
Why?
|
| Cholesterol | 6 | 2014 | 59 | 0.320 |
Why?
|
| Seafood | 3 | 2016 | 13 | 0.310 |
Why?
|
| Lipoproteins, LDL | 3 | 2008 | 7 | 0.300 |
Why?
|
| Tourniquets | 2 | 1998 | 4 | 0.300 |
Why?
|
| Cholesterol, LDL | 3 | 2010 | 29 | 0.300 |
Why?
|
| Risk | 4 | 2020 | 197 | 0.300 |
Why?
|
| Nutritive Value | 2 | 2019 | 21 | 0.300 |
Why?
|
| Wine | 2 | 2022 | 7 | 0.290 |
Why?
|
| Fatty Acids, Omega-3 | 4 | 2016 | 21 | 0.290 |
Why?
|
| Cohort Studies | 10 | 2022 | 1801 | 0.290 |
Why?
|
| Prospective Studies | 13 | 2022 | 1665 | 0.280 |
Why?
|
| Hyperhomocysteinemia | 1 | 2006 | 3 | 0.270 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 27 | 0.270 |
Why?
|
| Alleles | 2 | 2024 | 206 | 0.270 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2011 | 1069 | 0.270 |
Why?
|
| Patient Compliance | 5 | 2019 | 148 | 0.260 |
Why?
|
| Lipids | 5 | 2005 | 47 | 0.260 |
Why?
|
| Quality of Life | 2 | 2019 | 606 | 0.250 |
Why?
|
| United States | 8 | 2023 | 2043 | 0.250 |
Why?
|
| Diet Therapy | 1 | 2005 | 11 | 0.240 |
Why?
|
| Food, Fortified | 3 | 2012 | 8 | 0.240 |
Why?
|
| Telemedicine | 2 | 2018 | 104 | 0.240 |
Why?
|
| Mental Recall | 3 | 2019 | 61 | 0.230 |
Why?
|
| Weight Loss | 1 | 2005 | 121 | 0.230 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2004 | 1 | 0.230 |
Why?
|
| Body Mass Index | 5 | 2018 | 432 | 0.230 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2004 | 12 | 0.230 |
Why?
|
| Eating | 3 | 2019 | 57 | 0.220 |
Why?
|
| Patient Education as Topic | 1 | 2005 | 141 | 0.220 |
Why?
|
| Whole Grains | 1 | 2023 | 5 | 0.220 |
Why?
|
| Simvastatin | 6 | 2005 | 14 | 0.220 |
Why?
|
| Incidence | 5 | 2020 | 709 | 0.220 |
Why?
|
| Estradiol | 3 | 2001 | 35 | 0.210 |
Why?
|
| Pravastatin | 7 | 2005 | 10 | 0.210 |
Why?
|
| Animals | 9 | 2020 | 3551 | 0.210 |
Why?
|
| Motor Activity | 3 | 2015 | 311 | 0.210 |
Why?
|
| Time Factors | 6 | 2014 | 1347 | 0.210 |
Why?
|
| Health Education | 1 | 2023 | 44 | 0.200 |
Why?
|
| Nutrition Policy | 3 | 2010 | 9 | 0.200 |
Why?
|
| Arteriosclerosis | 2 | 2004 | 13 | 0.200 |
Why?
|
| Internet | 3 | 2018 | 86 | 0.200 |
Why?
|
| Food Supply | 2 | 2019 | 12 | 0.190 |
Why?
|
| Family Characteristics | 2 | 2019 | 19 | 0.190 |
Why?
|
| Positive-Pressure Respiration | 1 | 2021 | 11 | 0.190 |
Why?
|
| Plaque, Amyloid | 2 | 2014 | 144 | 0.190 |
Why?
|
| Lutein | 1 | 2021 | 5 | 0.190 |
Why?
|
| Zeaxanthins | 1 | 2021 | 5 | 0.190 |
Why?
|
| Mobile Applications | 1 | 2021 | 26 | 0.190 |
Why?
|
| Platelet Aggregation | 2 | 1998 | 5 | 0.190 |
Why?
|
| Anemia, Sickle Cell | 2 | 1992 | 16 | 0.190 |
Why?
|
| Estrogens, Conjugated (USP) | 1 | 2001 | 4 | 0.190 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2001 | 4 | 0.190 |
Why?
|
| Longitudinal Studies | 7 | 2024 | 1295 | 0.180 |
Why?
|
| Lipoproteins, HDL | 1 | 2001 | 22 | 0.180 |
Why?
|
| Hormone Replacement Therapy | 1 | 2001 | 33 | 0.180 |
Why?
|
| alpha-Tocopherol | 3 | 2023 | 11 | 0.180 |
Why?
|
| Anticholesteremic Agents | 2 | 1999 | 15 | 0.180 |
Why?
|
| Lactose | 2 | 1998 | 3 | 0.170 |
Why?
|
| Taiwan | 1 | 2020 | 7 | 0.170 |
Why?
|
| Fruit | 4 | 2019 | 25 | 0.170 |
Why?
|
| Neuropsychological Tests | 8 | 2016 | 1192 | 0.170 |
Why?
|
| Smoking | 3 | 2015 | 164 | 0.170 |
Why?
|
| Lactation | 2 | 1998 | 51 | 0.170 |
Why?
|
| Community Health Workers | 1 | 2020 | 26 | 0.170 |
Why?
|
| Video Games | 1 | 2019 | 4 | 0.160 |
Why?
|
| Feasibility Studies | 2 | 2017 | 199 | 0.160 |
Why?
|
| Interleukin-6 | 2 | 2018 | 73 | 0.160 |
Why?
|
| Patient Selection | 2 | 2017 | 184 | 0.160 |
Why?
|
| Public Health | 1 | 2020 | 68 | 0.160 |
Why?
|
| Psychological Tests | 3 | 2015 | 50 | 0.160 |
Why?
|
| Clergy | 1 | 2020 | 90 | 0.160 |
Why?
|
| Intensive Care Units | 1 | 2021 | 298 | 0.160 |
Why?
|
| Double-Blind Method | 4 | 2010 | 411 | 0.160 |
Why?
|
| Blood Specimen Collection | 2 | 1998 | 6 | 0.160 |
Why?
|
| Delay Discounting | 1 | 2019 | 24 | 0.160 |
Why?
|
| Neural Tube Defects | 1 | 1998 | 7 | 0.150 |
Why?
|
| Income | 1 | 2019 | 73 | 0.150 |
Why?
|
| Prodromal Symptoms | 1 | 2018 | 18 | 0.150 |
Why?
|
| Diet Records | 4 | 2021 | 11 | 0.150 |
Why?
|
| Antithrombins | 1 | 1998 | 2 | 0.150 |
Why?
|
| Body Composition | 1 | 2018 | 64 | 0.150 |
Why?
|
| Mass Screening | 1 | 2020 | 174 | 0.150 |
Why?
|
| Endothelium, Vascular | 1 | 1998 | 28 | 0.150 |
Why?
|
| Cardiopulmonary Bypass | 1 | 1998 | 16 | 0.150 |
Why?
|
| Temperament | 1 | 2018 | 13 | 0.150 |
Why?
|
| Mouth Mucosa | 1 | 2018 | 13 | 0.150 |
Why?
|
| Poverty | 1 | 2019 | 96 | 0.150 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2020 | 174 | 0.150 |
Why?
|
| Mouth Neoplasms | 1 | 2018 | 19 | 0.150 |
Why?
|
| Overweight | 1 | 2018 | 72 | 0.150 |
Why?
|
| Disease Progression | 3 | 2015 | 676 | 0.150 |
Why?
|
| Child Behavior | 1 | 2018 | 33 | 0.150 |
Why?
|
| Mother-Child Relations | 1 | 2018 | 31 | 0.150 |
Why?
|
| Genetic Variation | 1 | 1998 | 96 | 0.150 |
Why?
|
| MicroRNAs | 1 | 2018 | 52 | 0.140 |
Why?
|
| Breast Neoplasms | 1 | 2002 | 391 | 0.140 |
Why?
|
| Cholesterol, HDL | 2 | 2023 | 27 | 0.140 |
Why?
|
| Parenting | 1 | 2018 | 79 | 0.140 |
Why?
|
| Diet, Fat-Restricted | 2 | 2008 | 5 | 0.140 |
Why?
|
| Diet, Western | 1 | 2017 | 9 | 0.140 |
Why?
|
| Choice Behavior | 1 | 2017 | 45 | 0.130 |
Why?
|
| Exercise | 2 | 2018 | 416 | 0.130 |
Why?
|
| Energy Intake | 5 | 2021 | 80 | 0.130 |
Why?
|
| Educational Status | 4 | 2019 | 283 | 0.130 |
Why?
|
| Alcohol Drinking | 3 | 2022 | 75 | 0.130 |
Why?
|
| Mercury | 1 | 2016 | 10 | 0.130 |
Why?
|
| Independent Living | 1 | 2019 | 298 | 0.130 |
Why?
|
| gamma-Tocopherol | 2 | 2014 | 8 | 0.130 |
Why?
|
| Brain Chemistry | 1 | 2016 | 41 | 0.130 |
Why?
|
| C-Reactive Protein | 2 | 2023 | 92 | 0.120 |
Why?
|
| Calorimetry, Indirect | 1 | 2015 | 7 | 0.120 |
Why?
|
| End Stage Liver Disease | 1 | 2015 | 10 | 0.120 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 853 | 0.120 |
Why?
|
| Rest | 1 | 2015 | 31 | 0.120 |
Why?
|
| Vitamin A | 2 | 2002 | 8 | 0.120 |
Why?
|
| Research Design | 2 | 2019 | 190 | 0.120 |
Why?
|
| Urban Population | 3 | 2020 | 144 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 1994 | 18 | 0.120 |
Why?
|
| Osteoarthritis | 1 | 2018 | 316 | 0.120 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2014 | 1 | 0.120 |
Why?
|
| Caloric Restriction | 2 | 2023 | 15 | 0.120 |
Why?
|
| Follow-Up Studies | 7 | 2016 | 1722 | 0.110 |
Why?
|
| Blood-Brain Barrier | 1 | 2014 | 23 | 0.110 |
Why?
|
| Nutrition Therapy | 1 | 2014 | 8 | 0.110 |
Why?
|
| Minority Groups | 1 | 2015 | 78 | 0.110 |
Why?
|
| Tocopherols | 2 | 2023 | 8 | 0.110 |
Why?
|
| Adolescent | 7 | 2019 | 2172 | 0.110 |
Why?
|
| Peritoneal Dialysis | 1 | 2014 | 25 | 0.110 |
Why?
|
| Fatty Acids, Unsaturated | 3 | 2003 | 11 | 0.110 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2013 | 25 | 0.110 |
Why?
|
| Depression | 2 | 2013 | 400 | 0.110 |
Why?
|
| Methylmalonic Acid | 2 | 2013 | 2 | 0.110 |
Why?
|
| Vasodilation | 1 | 2013 | 3 | 0.110 |
Why?
|
| Phenols | 1 | 2013 | 4 | 0.110 |
Why?
|
| Stilbenes | 1 | 2013 | 6 | 0.110 |
Why?
|
| Flavonoids | 1 | 2013 | 16 | 0.110 |
Why?
|
| Immunomodulation | 1 | 2013 | 7 | 0.110 |
Why?
|
| Lignans | 1 | 2013 | 5 | 0.110 |
Why?
|
| Docosahexaenoic Acids | 2 | 2011 | 10 | 0.110 |
Why?
|
| Renal Dialysis | 1 | 2014 | 112 | 0.100 |
Why?
|
| Neurofibrillary Tangles | 1 | 2014 | 188 | 0.100 |
Why?
|
| Beverages | 3 | 2019 | 11 | 0.100 |
Why?
|
| Analysis of Variance | 3 | 2001 | 259 | 0.100 |
Why?
|
| Algorithms | 1 | 2015 | 357 | 0.100 |
Why?
|
| Indicators and Reagents | 2 | 2009 | 12 | 0.100 |
Why?
|
| Age Factors | 6 | 2018 | 744 | 0.100 |
Why?
|
| Fumarates | 1 | 2011 | 2 | 0.100 |
Why?
|
| Maleates | 1 | 2011 | 2 | 0.100 |
Why?
|
| Apolipoproteins E | 3 | 2022 | 241 | 0.090 |
Why?
|
| Lung | 2 | 1989 | 148 | 0.090 |
Why?
|
| Epidemiologic Studies | 1 | 2011 | 24 | 0.090 |
Why?
|
| Menstrual Cycle | 1 | 1991 | 17 | 0.090 |
Why?
|
| Clinical Trials as Topic | 3 | 2006 | 211 | 0.090 |
Why?
|
| Pilot Projects | 3 | 2023 | 397 | 0.090 |
Why?
|
| Cholesterol, VLDL | 1 | 2010 | 1 | 0.090 |
Why?
|
| Brain Infarction | 1 | 2011 | 71 | 0.090 |
Why?
|
| Cerebral Ventricles | 1 | 2011 | 18 | 0.090 |
Why?
|
| Placebos | 1 | 2010 | 67 | 0.090 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2001 | 18 | 0.080 |
Why?
|
| Residence Characteristics | 1 | 2011 | 204 | 0.080 |
Why?
|
| Postmenopause | 2 | 2001 | 47 | 0.080 |
Why?
|
| Lovastatin | 3 | 2001 | 7 | 0.080 |
Why?
|
| Contraceptives, Oral | 3 | 1979 | 5 | 0.080 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 571 | 0.080 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 1989 | 13 | 0.080 |
Why?
|
| Psychomotor Performance | 1 | 2011 | 204 | 0.080 |
Why?
|
| Blood Chemical Analysis | 2 | 2006 | 17 | 0.080 |
Why?
|
| Memory | 1 | 2010 | 292 | 0.080 |
Why?
|
| Lung Diseases | 1 | 1989 | 41 | 0.080 |
Why?
|
| Xanthophylls | 2 | 2004 | 2 | 0.080 |
Why?
|
| Cryptoxanthins | 2 | 2004 | 2 | 0.080 |
Why?
|
| Inflammation Mediators | 2 | 2019 | 64 | 0.080 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2008 | 2 | 0.080 |
Why?
|
| Chromatography | 1 | 1988 | 2 | 0.070 |
Why?
|
| Oxygen | 1 | 1988 | 67 | 0.070 |
Why?
|
| Body Weight | 2 | 2005 | 137 | 0.070 |
Why?
|
| Dietary Proteins | 2 | 2005 | 25 | 0.070 |
Why?
|
| Food Analysis | 1 | 2007 | 5 | 0.070 |
Why?
|
| Vitamin B 6 | 1 | 2006 | 3 | 0.070 |
Why?
|
| Inflammation | 2 | 2018 | 264 | 0.070 |
Why?
|
| Copper | 1 | 2006 | 17 | 0.070 |
Why?
|
| Specimen Handling | 1 | 2006 | 40 | 0.070 |
Why?
|
| Regression Analysis | 2 | 2002 | 249 | 0.070 |
Why?
|
| Fish Products | 1 | 2005 | 2 | 0.060 |
Why?
|
| Fishes | 1 | 2005 | 4 | 0.060 |
Why?
|
| Diet, Protein-Restricted | 1 | 2005 | 4 | 0.060 |
Why?
|
| Growth | 1 | 2005 | 6 | 0.060 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2005 | 5 | 0.060 |
Why?
|
| Ketone Bodies | 1 | 2005 | 5 | 0.060 |
Why?
|
| Ketosis | 1 | 2005 | 7 | 0.060 |
Why?
|
| Dietary Carbohydrates | 1 | 2005 | 11 | 0.060 |
Why?
|
| Geriatric Assessment | 3 | 2013 | 198 | 0.060 |
Why?
|
| Diet, Reducing | 1 | 2005 | 11 | 0.060 |
Why?
|
| Child | 3 | 2018 | 1326 | 0.060 |
Why?
|
| Bone Remodeling | 1 | 2005 | 48 | 0.060 |
Why?
|
| Linear Models | 2 | 2016 | 238 | 0.060 |
Why?
|
| Chemokine CCL2 | 1 | 2005 | 18 | 0.060 |
Why?
|
| Hyperlipoproteinemias | 1 | 2004 | 1 | 0.060 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2004 | 26 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2011 | 3283 | 0.060 |
Why?
|
| Niacin | 1 | 2004 | 3 | 0.060 |
Why?
|
| Child Development | 1 | 2005 | 62 | 0.060 |
Why?
|
| Epilepsy | 1 | 2005 | 64 | 0.060 |
Why?
|
| Hemoglobins | 2 | 1989 | 76 | 0.060 |
Why?
|
| Nutrition Disorders | 1 | 2003 | 3 | 0.060 |
Why?
|
| Sex Factors | 3 | 2018 | 456 | 0.060 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2023 | 10 | 0.050 |
Why?
|
| Hemorheology | 1 | 2003 | 1 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2023 | 25 | 0.050 |
Why?
|
| Drinking | 1 | 2003 | 4 | 0.050 |
Why?
|
| Genotype | 1 | 2024 | 350 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2019 | 106 | 0.050 |
Why?
|
| Beer | 1 | 2022 | 1 | 0.050 |
Why?
|
| Alcoholic Beverages | 1 | 2022 | 2 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2002 | 29 | 0.050 |
Why?
|
| Probability | 1 | 2002 | 86 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2023 | 197 | 0.050 |
Why?
|
| Intermittent Positive-Pressure Ventilation | 1 | 2021 | 4 | 0.050 |
Why?
|
| Reference Values | 2 | 2003 | 189 | 0.050 |
Why?
|
| Vitamin E Deficiency | 1 | 1981 | 1 | 0.050 |
Why?
|
| Arachidonic Acids | 1 | 1981 | 7 | 0.050 |
Why?
|
| Fast Foods | 1 | 2021 | 5 | 0.050 |
Why?
|
| Blood Platelets | 1 | 1981 | 39 | 0.050 |
Why?
|
| Contraceptives, Oral, Combined | 2 | 1978 | 2 | 0.050 |
Why?
|
| Models, Animal | 1 | 2001 | 111 | 0.050 |
Why?
|
| Mice | 2 | 2020 | 1380 | 0.050 |
Why?
|
| Horses | 1 | 2001 | 10 | 0.050 |
Why?
|
| Heptanoic Acids | 1 | 2001 | 5 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2001 | 38 | 0.050 |
Why?
|
| Particle Size | 1 | 2001 | 51 | 0.050 |
Why?
|
| Pyrroles | 1 | 2001 | 22 | 0.050 |
Why?
|
| Creatinine | 2 | 1996 | 51 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2018 | 652 | 0.050 |
Why?
|
| Ethanol | 1 | 2022 | 120 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2021 | 130 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2001 | 105 | 0.040 |
Why?
|
| Rodentia | 1 | 2020 | 7 | 0.040 |
Why?
|
| Mouth | 1 | 2020 | 14 | 0.040 |
Why?
|
| Plant Extracts | 1 | 2020 | 14 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 473 | 0.040 |
Why?
|
| Neurodegenerative Diseases | 1 | 2021 | 118 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2001 | 127 | 0.040 |
Why?
|
| Religion | 1 | 2020 | 40 | 0.040 |
Why?
|
| Safety-net Providers | 1 | 2019 | 6 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2001 | 146 | 0.040 |
Why?
|
| Computers, Handheld | 1 | 2019 | 12 | 0.040 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2019 | 66 | 0.040 |
Why?
|
| Nutritional Requirements | 2 | 2012 | 15 | 0.040 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 1979 | 6 | 0.040 |
Why?
|
| Rats | 1 | 2020 | 634 | 0.040 |
Why?
|
| Knee | 1 | 2018 | 43 | 0.040 |
Why?
|
| Executive Function | 1 | 2019 | 111 | 0.040 |
Why?
|
| Hyperphagia | 1 | 1998 | 3 | 0.040 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 1998 | 5 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2018 | 77 | 0.040 |
Why?
|
| Attention | 1 | 2019 | 119 | 0.040 |
Why?
|
| Thromboplastin | 1 | 1998 | 5 | 0.040 |
Why?
|
| Gingiva | 1 | 2018 | 3 | 0.040 |
Why?
|
| Streptococcus | 1 | 2018 | 3 | 0.040 |
Why?
|
| Catechin | 1 | 2018 | 4 | 0.040 |
Why?
|
| Malondialdehyde | 1 | 1998 | 1 | 0.040 |
Why?
|
| Staphylococcus | 1 | 2018 | 10 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2019 | 279 | 0.040 |
Why?
|
| Epithelium | 1 | 2018 | 20 | 0.040 |
Why?
|
| Self Concept | 1 | 1998 | 41 | 0.040 |
Why?
|
| Blood Preservation | 1 | 1998 | 1 | 0.040 |
Why?
|
| Smokers | 1 | 2018 | 11 | 0.040 |
Why?
|
| Uric Acid | 1 | 1998 | 14 | 0.040 |
Why?
|
| Students | 1 | 1979 | 51 | 0.040 |
Why?
|
| Creatine Kinase | 1 | 1998 | 20 | 0.040 |
Why?
|
| Isoenzymes | 1 | 1998 | 50 | 0.040 |
Why?
|
| Heart Atria | 1 | 1998 | 25 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2018 | 26 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2005 | 330 | 0.040 |
Why?
|
| Pressure | 1 | 1998 | 58 | 0.040 |
Why?
|
| Comorbidity | 1 | 2019 | 468 | 0.040 |
Why?
|
| Mental Health | 1 | 2019 | 113 | 0.040 |
Why?
|
| Infant Nutritional Physiological Phenomena | 1 | 1998 | 63 | 0.040 |
Why?
|
| Thrombosis | 1 | 1998 | 48 | 0.040 |
Why?
|
| Contraceptive Agents, Female | 1 | 1977 | 1 | 0.040 |
Why?
|
| Mestranol | 1 | 1977 | 1 | 0.040 |
Why?
|
| Norethindrone | 1 | 1977 | 1 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2018 | 106 | 0.040 |
Why?
|
| Cytokines | 1 | 1999 | 224 | 0.040 |
Why?
|
| Adaptation, Psychological | 1 | 1998 | 154 | 0.040 |
Why?
|
| Blood | 1 | 1977 | 18 | 0.040 |
Why?
|
| Pediatric Obesity | 1 | 2018 | 49 | 0.040 |
Why?
|
| Computer Simulation | 1 | 1998 | 178 | 0.030 |
Why?
|
| Logistic Models | 3 | 2005 | 353 | 0.030 |
Why?
|
| Research | 1 | 1977 | 40 | 0.030 |
Why?
|
| Obstetric Labor, Premature | 1 | 1996 | 2 | 0.030 |
Why?
|
| Postpartum Period | 1 | 1996 | 17 | 0.030 |
Why?
|
| Microbiota | 1 | 2018 | 102 | 0.030 |
Why?
|
| Neuroprotection | 1 | 2016 | 5 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 9 | 0.030 |
Why?
|
| Gene-Environment Interaction | 1 | 2016 | 17 | 0.030 |
Why?
|
| Selenium | 1 | 2016 | 9 | 0.030 |
Why?
|
| Fasting | 2 | 2008 | 22 | 0.030 |
Why?
|
| Cerebellum | 1 | 2016 | 45 | 0.030 |
Why?
|
| Frontal Lobe | 1 | 2016 | 81 | 0.030 |
Why?
|
| Temporal Lobe | 1 | 2016 | 80 | 0.030 |
Why?
|
| Heterozygote | 1 | 2016 | 96 | 0.030 |
Why?
|
| Milk, Human | 1 | 1998 | 157 | 0.030 |
Why?
|
| Pregnancy | 1 | 1996 | 312 | 0.030 |
Why?
|
| Program Development | 1 | 2015 | 62 | 0.030 |
Why?
|
| Mortality | 1 | 1995 | 81 | 0.030 |
Why?
|
| Autopsy | 1 | 2016 | 328 | 0.030 |
Why?
|
| Hypolipoproteinemias | 1 | 1994 | 1 | 0.030 |
Why?
|
| American Cancer Society | 1 | 2014 | 5 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 242 | 0.030 |
Why?
|
| Interviews as Topic | 1 | 2015 | 132 | 0.030 |
Why?
|
| Dietary Fiber | 1 | 2014 | 24 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2015 | 321 | 0.030 |
Why?
|
| Registries | 1 | 2015 | 170 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2005 | 122 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 567 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2013 | 247 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2013 | 234 | 0.020 |
Why?
|
| Erythrocytes | 1 | 2012 | 20 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2013 | 122 | 0.020 |
Why?
|
| Mexican Americans | 1 | 2012 | 28 | 0.020 |
Why?
|
| Hematocrit | 2 | 2003 | 14 | 0.020 |
Why?
|
| Confidence Intervals | 2 | 2005 | 90 | 0.020 |
Why?
|
| Models, Biological | 1 | 2013 | 292 | 0.020 |
Why?
|
| Infant | 2 | 2005 | 541 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2012 | 592 | 0.020 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 1989 | 17 | 0.020 |
Why?
|
| Satiation | 1 | 2008 | 2 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 1988 | 4 | 0.020 |
Why?
|
| Mice, Inbred Strains | 1 | 1988 | 25 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 1988 | 33 | 0.020 |
Why?
|
| Dehydroascorbic Acid | 1 | 1988 | 1 | 0.020 |
Why?
|
| 2,3-Diketogulonic Acid | 1 | 1988 | 1 | 0.020 |
Why?
|
| Chemistry | 1 | 1988 | 2 | 0.020 |
Why?
|
| Chemical Phenomena | 1 | 1988 | 4 | 0.020 |
Why?
|
| Drug Stability | 1 | 1988 | 3 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 1988 | 14 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1992 | 546 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 1987 | 107 | 0.020 |
Why?
|
| Alkaline Phosphatase | 1 | 2005 | 19 | 0.020 |
Why?
|
| Osteocalcin | 1 | 2005 | 27 | 0.020 |
Why?
|
| Collagen | 1 | 2005 | 78 | 0.020 |
Why?
|
| Body Height | 1 | 2005 | 36 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2005 | 64 | 0.010 |
Why?
|
| Tumor Necrosis Factor Decoy Receptors | 1 | 2004 | 2 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2004 | 3 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2004 | 3 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2005 | 54 | 0.010 |
Why?
|
| Data Collection | 1 | 2005 | 88 | 0.010 |
Why?
|
| Censuses | 1 | 2004 | 9 | 0.010 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2003 | 9 | 0.010 |
Why?
|
| Elasticity | 1 | 2003 | 31 | 0.010 |
Why?
|
| Fluid Therapy | 1 | 2003 | 33 | 0.010 |
Why?
|
| Cluster Analysis | 1 | 2002 | 45 | 0.010 |
Why?
|
| Prostaglandins E | 1 | 1981 | 4 | 0.010 |
Why?
|
| Phosphatidylcholines | 1 | 1981 | 6 | 0.010 |
Why?
|
| Phospholipids | 1 | 1981 | 10 | 0.010 |
Why?
|
| Creatine | 1 | 1981 | 6 | 0.010 |
Why?
|
| Phosphorus | 1 | 1981 | 7 | 0.010 |
Why?
|
| Dinoprostone | 1 | 1981 | 17 | 0.010 |
Why?
|
| Thrombin | 1 | 1981 | 15 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 1981 | 14 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2002 | 103 | 0.010 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2001 | 2 | 0.010 |
Why?
|
| Rabbits | 1 | 1981 | 181 | 0.010 |
Why?
|
| Indoles | 1 | 2001 | 34 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2001 | 59 | 0.010 |
Why?
|
| Receptors, Interleukin-1 | 1 | 1999 | 4 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 1999 | 18 | 0.010 |
Why?
|
| Virginia | 1 | 1979 | 3 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 1999 | 47 | 0.010 |
Why?
|
| Medroxyprogesterone | 1 | 1998 | 1 | 0.010 |
Why?
|
| Hemolysis | 1 | 1978 | 5 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 1978 | 6 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1999 | 180 | 0.010 |
Why?
|
| Contraceptive Agents | 1 | 1977 | 1 | 0.010 |
Why?
|
| Norethynodrel | 1 | 1977 | 1 | 0.010 |
Why?
|
| Family Planning Services | 1 | 1977 | 2 | 0.010 |
Why?
|
| Contraception | 1 | 1977 | 3 | 0.010 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 1977 | 2 | 0.010 |
Why?
|
| Physiology | 1 | 1977 | 4 | 0.010 |
Why?
|
| Biology | 1 | 1977 | 8 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2005 | 3285 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1998 | 563 | 0.010 |
Why?
|
| Telephone | 1 | 1995 | 23 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 1994 | 27 | 0.010 |
Why?
|